ChartMill assigns a Buy % Consensus number of 80% to QTTB. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-12 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-02-11 | BMO Capital | Downgrade | Outperform -> Market Perform |
| 2025-02-11 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2024-12-12 | Guggenheim | Downgrade | Buy -> Neutral |
| 2024-12-12 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-12-11 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-12-11 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-12-11 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2024-12-11 | Raymond James | Downgrade | Strong Buy -> Outperform |
| 2024-12-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-12-06 | BMO Capital | Initiate | Outperform |
| 2024-10-24 | Raymond James | Initiate | Strong Buy |
| 2024-09-11 | Wells Fargo | Initiate | Overweight |
| 2024-06-17 | Guggenheim | Initiate | Buy |
| 2024-05-21 | Leerink Partners | Initiate | Outperform |
| 2024-04-11 | Oppenheimer | Initiate | Outperform |
| 2024-04-02 | Piper Sandler | Initiate | Overweight |
9 analysts have analysed QTTB and the average price target is 11.56 USD. This implies a price increase of 239% is expected in the next year compared to the current price of 3.41.
The consensus rating for Q32 BIO INC (QTTB) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.